Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Test Euthyrox · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1:Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox® | EXPERIMENTAL | Participants will receive single oral dose of Test Euthyrox® on in treatment period 1, followed by single oral dose of Reference Euthyrox® in treatment period 2, followed by single oral dose of Test Euthyrox® in treatment period 3, followed by single oral dose of Reference Euthyrox in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period. |
| Sequence 2:Reference Euthyrox®, then Test Euthyrox®, then Reference Euthyrox®, then Test Euthyrox® | EXPERIMENTAL | Participants will receive single oral dose of Reference Euthyrox® in treatment period 1, followed by single oral dose of Test Euthyrox® in treatment period 2, followed by single oral dose of Reference Euthyrox® in treatment period 3, followed by single oral dose of Test Euthyrox® in treatment period 4. Participants will remain resident until Day 4 for each treatment period and there will be a washout period of 53 days between each treatment period. |
| Name | Type | Description |
|---|---|---|
| Test Euthyrox® | DRUG | Participants will receive single oral dose of Test Euthyrox® either in treatment period 1, 2, 3 or 4. |
| Reference Euthyrox® | DRUG | Participants will receive single oral dose of Reference Euthyrox® either in treatment period 1, 2, 3 or 4. |
Inclusion Criteria: * Participants have a body weight within 45 to 75 kilogram (kg) for females and 55 to 85 kg for males and Body mass index (BMI) within the range 19.0 to 26.0 kilograms per meter square (kg/m\^2) * Non-smoker for at least 3 months * Contraceptive use by males or females will be c...
Euthyrox is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its bioequivalence. The drug is being developed by Merck KGaA.
Euthyrox is being developed by Merck KGaA, a company traded under the ticker MKGAF. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers.
Euthyrox is in Phase 1 clinical development. It has one completed trial with 56 participants, all healthy volunteers. The drug is investigational and has not been approved for any indication.
Euthyrox has one completed Phase 1 trial, NCT05174000, which studied the bioequivalence of Euthyrox tablets from different manufacturing sites. The trial enrolled 56 healthy volunteers in China and was completed.
Euthyrox is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. One trial, NCT05174000, has been completed in healthy volunteers to assess bioequivalence.